{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:54:07Z","timestamp":1786982047241,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T00:00:00Z","timestamp":1641600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pharmacosmos A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["OBES SURG"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Iron deficiency is common following bariatric surgery, and treatment with intravenous iron is often required. This post hoc analysis of data from two randomized, open-label, multicenter trials evaluated the efficacy and safety of ferric derisomaltose (FDI; formerly iron isomaltoside 1000) versus iron sucrose (IS) over 4\u00a0weeks in adults with iron deficiency anemia (IDA) resulting from prior bariatric surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Data were pooled for participants who received FDI or IS in the PROVIDE or FERWON-IDA trials for the treatment of IDA post bariatric surgery. Efficacy outcomes included changes in hemoglobin (Hb) and iron parameters; safety outcomes included the incidence of adverse drug reactions (ADRs), serious or severe hypersensitivity reactions (HSRs), and hypophosphatemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 159 patients. Mean (standard deviation) cumulative iron doses were 1199 (\u00b1\u2009347) mg for FDI and 937 (\u00b1\u2009209) mg for IS. Compared with IS, FDI resulted in a faster and more pronounced Hb response, and a higher proportion of responders (Hb level increase\u2009\u2265\u20092\u00a0g\/dL from baseline) at all time points. The incidence of ADRs was similar with FDI and IS (15.1% and 18.2%, respectively), with no serious ADRs or serious or severe HSRs reported. The incidence of hypophosphatemia was low and similar in both treatment groups, with no cases of severe hypophosphatemia observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with IDA resulting from bariatric surgery, FDI produced a faster and more pronounced Hb response than IS. Both FDI and IS were well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11695-021-05858-0","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T12:02:21Z","timestamp":1641643341000},"page":"810-818","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-8647","authenticated-orcid":false,"given":"Michael","family":"Auerbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen M.","family":"Achebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars L.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,8]]},"reference":[{"issue":"15","key":"5858_CR1","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3748\/wjg.v16.i15.1867","volume":"16","author":"DV Avgerinos","year":"2010","unstructured":"Avgerinos DV, Llaguna OH, Seigerman M, et al. Incidence and risk factors for the development of anemia following gastric bypass surgery. World J Gastroenterol. 2010;16(15):1867\u201370.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5858_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3945\/ajcn.2009.27699","volume":"90","author":"M Ruz","year":"2009","unstructured":"Ruz M, Carrasco F, Rojas P, et al. Iron absorption and iron status are reduced after Roux-en-Y gastric bypass. Am J Clin Nutr. 2009;90(3):527\u201332.","journal-title":"Am J Clin Nutr"},{"issue":"9","key":"5858_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrendo.2012.48","volume":"8","author":"BS Bal","year":"2012","unstructured":"Bal BS, Finelli FC, Shope TR, et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8(9):544\u201356.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"5858_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ajh.21106","volume":"83","author":"AL Love","year":"2008","unstructured":"Love AL, Billett HH. Obesity, bariatric surgery, and iron deficiency: true, true, true and related. Am J Hematol. 2008;83(5):403\u20139.","journal-title":"Am J Hematol"},{"issue":"6","key":"5858_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/apt.12872","volume":"40","author":"J Stein","year":"2014","unstructured":"Stein J, Stier C, Raab H, et al. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582\u2013609.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"5858_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11695-013-1042-8","volume":"24","author":"I Gesquiere","year":"2014","unstructured":"Gesquiere I, Lannoo M, Augustijns P, et al. Iron deficiency after Roux-en-Y gastric bypass: insufficient iron absorption from oral iron supplements. Obes Surg. 2014;24(1):56\u201361.","journal-title":"Obes Surg"},{"issue":"2","key":"5858_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF02090203","volume":"39","author":"KE Behrns","year":"1994","unstructured":"Behrns KE, Smith CD, Sarr MG. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. Dig Dis Sci. 1994;39(2):315\u201320.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"5858_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000339769","volume":"5","author":"J Ortega","year":"2012","unstructured":"Ortega J, Ortega-Evangelio G, Cassinello N, et al. What are obese patients able to eat after Roux-en-Y gastric bypass? Obes Facts. 2012;5(3):339\u201348.","journal-title":"Obes Facts"},{"issue":"1","key":"5858_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/asheducation-2016.1.57","volume":"2016","author":"M Auerbach","year":"2016","unstructured":"Auerbach M, Deloughery T. Single-dose intravenous iron for iron deficiency: a new paradigm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):57\u201366.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"5858_CR10","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1007\/s00464-019-07092-3","volume":"34","author":"G Enani","year":"2020","unstructured":"Enani G, Bilgic E, Lebedeva E, et al. The incidence of iron deficiency anemia post-Roux-en-Y gastric bypass and sleeve gastrectomy: a systematic review. Surg Endosc. 2020;34(7):3002\u201310.","journal-title":"Surg Endosc"},{"issue":"15","key":"5858_CR11","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/bloodadvances.2020001880","volume":"4","author":"Z Gowanlock","year":"2020","unstructured":"Gowanlock Z, Lezhanska A, Conroy M, et al. Iron deficiency following bariatric surgery: a retrospective cohort study. Blood Adv. 2020;4(15):3639\u201347.","journal-title":"Blood Adv"},{"issue":"2","key":"5858_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1753-4887.2008.00145.x","volume":"67","author":"JP McClung","year":"2009","unstructured":"McClung JP, Karl JP. Iron deficiency and obesity: the contribution of inflammation and diminished iron absorption. Nutr Rev. 2009;67(2):100\u20134.","journal-title":"Nutr Rev"},{"issue":"7","key":"5858_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/ijo.2008.43","volume":"32","author":"MB Zimmermann","year":"2008","unstructured":"Zimmermann MB, Zeder C, Muthayya S, et al. Adiposity in women and children from transition countries predicts decreased iron absorption, iron deficiency and a reduced response to iron fortification. Int J Obes (Lond). 2008;32(7):1098\u2013104.","journal-title":"Int J Obes (Lond)"},{"key":"5858_CR14","unstructured":"National Heart, Lung, and Blood Institute (NHLBI). Your guide to anemia: National Institutes of Health (NIH). NIH publication number: 11\u20137629; 2011."},{"issue":"2","key":"5858_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/2327-6924.12268","volume":"28","author":"A Rabel","year":"2016","unstructured":"Rabel A, Leitman SF, Miller JL. Ask about ice, then consider iron. J Am Assoc Nurse Pract. 2016;28(2):116\u201320.","journal-title":"J Am Assoc Nurse Pract"},{"issue":"11","key":"5858_CR16","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/archinte.165.11.1286","volume":"165","author":"RP Allen","year":"2005","unstructured":"Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286\u201392.","journal-title":"Arch Intern Med"},{"issue":"5","key":"5858_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000355480","volume":"6","author":"M Fried","year":"2013","unstructured":"Fried M, Yumuk V, Oppert JM, et al. European Association for the Study of Obesity; International Federation for the Surgery of Obesity \u2013 European Chapter. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449\u201368.","journal-title":"Obes Facts"},{"issue":"12","key":"5858_CR18","first-page":"1346","volume":"25","author":"JI Mechanick","year":"2019","unstructured":"Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures \u2013 2019 update: cosponsored by American Association of Clinical Endocrinologists\/American College of Endocrinology, The Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists \u2013 executive summary. Endocr Pract. 2019;25(12):1346\u201359.","journal-title":"Endocr Pract"},{"issue":"17","key":"5858_CR19","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2015-05-642223","volume":"126","author":"D Moretti","year":"2015","unstructured":"Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126(17):1981\u20139.","journal-title":"Blood"},{"issue":"11","key":"5858_CR20","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1016\/S2352-3026(17)30182-5","volume":"4","author":"NU Stoffel","year":"2017","unstructured":"Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017;4(11):e524\u201333.","journal-title":"Lancet Haematol"},{"issue":"4","key":"5858_CR21","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/ajcn\/nqaa174","volume":"112","author":"MA Uyoga","year":"2020","unstructured":"Uyoga MA, Mikulic N, Paganini D, et al. The effect of iron dosing schedules on plasma hepcidin and iron absorption in Kenyan infants. Am J Clin Nutr. 2020;112(4):1132\u201341.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"5858_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.3945\/ajcn.112.039255","volume":"96","author":"M Ruz","year":"2012","unstructured":"Ruz M, Carrasco F, Rojas P, et al. Heme- and nonheme-iron absorption and iron status 12 mo after sleeve gastrectomy and Roux-en-Y gastric bypass in morbidly obese women. Am J Clin Nutr. 2012;96(4):810\u20137.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"5858_CR23","doi-asserted-by":"publisher","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","volume":"10","author":"Z Tolkien","year":"2015","unstructured":"Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10(2):e0117383.","journal-title":"PLoS One"},{"issue":"12","key":"5858_CR24","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1016\/j.clnu.2020.04.010","volume":"39","author":"W Schijns","year":"2020","unstructured":"Schijns W, Boerboom A, de Bruyn Kops M, et al. A randomized controlled trial comparing oral and intravenous iron supplementation after Roux-en-Y gastric bypass surgery. Clin Nutr. 2020;39(12):3779\u201385.","journal-title":"Clin Nutr"},{"key":"5858_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2147\/TCRM.S25882","volume":"7","author":"S Bhandari","year":"2011","unstructured":"Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag. 2011;7:501\u20139.","journal-title":"Ther Clin Risk Manag"},{"key":"5858_CR26","doi-asserted-by":"publisher","first-page":"4585164","DOI":"10.1155\/2017\/4585164","volume":"2017","author":"SO Frigstad","year":"2017","unstructured":"Frigstad SO, Haaber A, Bajor A, et al. The NIMO Scandinavian Study: a prospective observational study of iron isomaltoside treatment in patients with iron deficiency. Gastroenterol Res Pract. 2017;2017:4585164.","journal-title":"Gastroenterol Res Pract"},{"key":"5858_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/CEOR.S139525","volume":"9","author":"RF Pollock","year":"2017","unstructured":"Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. Clinicoecon Outcomes Res. 2017;9:475\u201383.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"12","key":"5858_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/17425247.2017.1393412","volume":"14","author":"RF Pollock","year":"2017","unstructured":"Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv. 2017;14(12):1439\u201346.","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"5858_CR29","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1007\/s12325-018-0827-5","volume":"35","author":"RF Pollock","year":"2018","unstructured":"Pollock RF, Muduma G. An economic evaluation of iron isomaltoside 1000 versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in Denmark. Adv Ther. 2018;35(12):2128\u201337.","journal-title":"Adv Ther"},{"issue":"7","key":"5858_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/13696998.2020.1745535","volume":"23","author":"RF Pollock","year":"2020","unstructured":"Pollock RF, Muduma G. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. J Med Econ. 2020;23(7):751\u20139.","journal-title":"J Med Econ"},{"key":"5858_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEOR.S284959","volume":"13","author":"RF Pollock","year":"2021","unstructured":"Pollock RF, Muduma G. An economic analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Norway, Sweden, and Finland. Clinicoecon Outcomes Res. 2021;13:9\u201318.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"5858_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/trf.15837","volume":"60","author":"M Achebe","year":"2020","unstructured":"Achebe M, DeLoughery TG. Clinical data for intravenous iron \u2013 debunking the hype around hypersensitivity. Transfusion. 2020;60(6):1154\u20139.","journal-title":"Transfusion"},{"issue":"11","key":"5858_CR33","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","volume":"99","author":"D Rampton","year":"2014","unstructured":"Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671\u20136.","journal-title":"Haematologica"},{"issue":"1","key":"5858_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","volume":"90","author":"T Avni","year":"2015","unstructured":"Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12\u201323.","journal-title":"Mayo Clin Proc"},{"key":"5858_CR35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S243462","volume":"16","author":"JA Glaspy","year":"2020","unstructured":"Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag. 2020;16:245\u201359.","journal-title":"Ther Clin Risk Manag"},{"issue":"5","key":"5858_CR36","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/bcp.14643","volume":"87","author":"B Schaefer","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, et al. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside \u2013 a systematic review and meta-analysis. Br J Clin Pharmacol. 2021;87(5):2256\u201373.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"5858_CR37","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432\u201343.","journal-title":"JAMA"},{"issue":"4","key":"5858_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","volume":"26","author":"H Zoller","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266\u201375.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"5858_CR39","unstructured":"Monofer\u00ae (ferric derisomaltose). Summary of Product Characteristics. Pharmacosmos UK Ltd.; 2020."},{"key":"5858_CR40","unstructured":"Monoferric\u00ae (ferric derisomaltose) injection for intravenous use. Prescribing information. Pharmacosmos A\/S; 2020."},{"issue":"6","key":"5858_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ajh.26124","volume":"96","author":"M Auerbach","year":"2021","unstructured":"Auerbach M, Henry D, DeLoughery TG. Intravenous ferric derisomaltose for the treatment of iron deficiency anemia. Am J Hematol. 2021;96(6):727\u201334.","journal-title":"Am J Hematol"},{"issue":"1","key":"5858_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/17474086.2021.1858406","volume":"14","author":"X Kassianides","year":"2021","unstructured":"Kassianides X, Bodington R, Bhandari S. An evaluation of ferric derisomaltose as a treatment for anemia. Expert Rev Hematol. 2021;14(1):7\u201329.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"5858_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ajh.24633","volume":"92","author":"R Derman","year":"2017","unstructured":"Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92(3):286\u201391.","journal-title":"Am J Hematol"},{"issue":"9","key":"5858_CR44","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ajh.25564","volume":"94","author":"M Auerbach","year":"2019","unstructured":"Auerbach M, Henry D, Derman RJ, et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007\u201314.","journal-title":"Am J Hematol"},{"key":"5858_CR45","unstructured":"Venofer\u00ae (iron sucrose) 20 mg iron\/ml, solution for injection or concentrate for solution for infusion. Summary of Product Characteristics. Vifor Pharma UK Ltd.; 2020."},{"key":"5858_CR46","unstructured":"Venofer\u00ae (iron sucrose) injection, for intravenous use. Prescribing information. American Regent, Inc.; 2019."},{"issue":"9","key":"5858_CR47","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s11695-013-0939-6","volume":"23","author":"M Malone","year":"2013","unstructured":"Malone M, Barish C, He A, et al. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients. Obes Surg. 2013;23(9):1413\u201320.","journal-title":"Obes Surg"},{"issue":"4","key":"5858_CR48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/apt.15386","volume":"50","author":"TE Detlie","year":"2019","unstructured":"Detlie TE, Lindstr\u00f8m JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397\u2013406.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5858_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/17474086.2019.1575202","volume":"12","author":"RF Pollock","year":"2019","unstructured":"Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol. 2019;12(2):129\u201336.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"5858_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17474086.2020.1709437","volume":"13","author":"RF Pollock","year":"2020","unstructured":"Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187\u201395.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"5858_CR51","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/cen.13531","volume":"88","author":"S Hewitt","year":"2018","unstructured":"Hewitt S, Aasheim ET, S\u00f8vik TT, et al. Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery. Clin Endocrinol (Oxf). 2018;88(3):372\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"5858_CR52","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s11695-017-2932-y","volume":"28","author":"JH Wei","year":"2018","unstructured":"Wei JH, Lee WJ, Chong K, et al. High incidence of secondary hyperparathyroidism in bariatric patients: comparing different procedures. Obes Surg. 2018;28(3):798\u2013804.","journal-title":"Obes Surg"},{"issue":"10","key":"5858_CR53","doi-asserted-by":"publisher","first-page":"E276","DOI":"10.1002\/ajh.25920","volume":"95","author":"MM Achebe","year":"2020","unstructured":"Achebe MM, Glaspy J, Kalra PA, et al. A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: the FERWON-EXT trial. Am J Hematol. 2020;95(10):E276\u20139.","journal-title":"Am J Hematol"}],"container-title":["Obesity Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-021-05858-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11695-021-05858-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11695-021-05858-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T22:44:27Z","timestamp":1666305867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11695-021-05858-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,8]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["5858"],"URL":"https:\/\/doi.org\/10.1007\/s11695-021-05858-0","relation":{},"ISSN":["0960-8923","1708-0428"],"issn-type":[{"value":"0960-8923","type":"print"},{"value":"1708-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,8]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.A. receives research funding for data management from Covis Pharma and has given educational non-promotional talks for Pharmacosmos A\/S and Pfizer. M.M.A. has been on scientific advisory boards for Pharmacosmos A\/S. L.L.T. is employed by Pharmacosmos A\/S. R.J.D. has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}